Valeant Pharma (VRX) Posts non-GAAP EPS of $0.58; Raises FY09 EPS Guidance
VRX Hot Sheet
EPS Growth %: +4,850.0%Financial Fact:
Restructuring and acquisition-related costs: 10.71M
Today's EPS Names:
TLB, TNP, MENT, More
Valeant Pharmaceuticals International (NYSE: VRX) reports Q3 non-GAAP EPS of $0.58, 9 cents better than the analyst estimate of $0.49. Revenue for the quarter was $220 million, which compares to the estimate of $193.53 million.
Raises FY09 EPS guidance to $2.10 - $2.20, up from $1.90 - $2.10.
Raises FY09 EPS guidance to $2.10 - $2.20, up from $1.90 - $2.10.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Semtech Corp (SMTC) Misses Q1 EPS by 4c; Guides Q2
- Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
